Vilon: The Immune Bioregulator
Last updated: May 2026
Vilon (L-Lys-L-Glu) is the simplest Khavinson bioregulator — a dipeptide derived from thymus tissue that modulates immune cell proliferation and differentiation. Animal studies show it inhibits spontaneous tumor growth and increases lifespan in mice.
🧪 Buy Vilon at Swiss Chems →Lys-Glu
Origin
Framework
📋 On this page
What Is Vilon?
Vilon is the synthetic minimal sequence identified by Khavinson's team as one of the active components of Thymalin (a thymus extract). At just two amino acids, it's the smallest bioregulator peptide — yet it retains immunomodulatory properties in cell and animal models.
Mimics thymic peptide signaling to support T-cell proliferation and differentiation. May help restore adaptive immune function that declines with thymic involution during aging.
Despite being only two amino acids, Vilon crosses cell and nuclear membranes to interact with DNA regulatory regions, influencing gene expression in immune cells.
In mouse models, Vilon inhibited spontaneous tumor growth — likely through enhanced immune surveillance rather than direct cytotoxicity.
In THP-1 monocyte/macrophage cells, Vilon regulated proliferative activity and inflammatory pathway gene expression (PMC8999041).
What the Research Shows
Context: Vilon research comes from the Khavinson bioregulator program and peer-reviewed publications including PMC-indexed studies. Evidence is primarily in vitro and animal studies. No large-scale human clinical trials exist.
Side Effects & Safety Profile
Oral Vilon: Research vs Community Claims
Vilon has historically been administered as a research injectable. A wave of community interest in 2026 (Protocol VILON capsules, the "VrillON" bioregulator stack) brought oral dosing into peptide circles. Here is what the literature supports and where the gap begins.
The honest summary: Two rodent studies document oral Vilon affecting intestinal enzyme activity in aged rats. No human bioavailability, pharmacokinetic, or efficacy data exists. Energy / immune / recovery claims circulating on X are anecdotal and not clinically validated.
Khavinson VK et al. (2001, PMID 11586413) tested oral Vilon in 3- and 11-month-old Wistar rats and reported shifts in digestive enzyme activity across gastrointestinal regions. Vinogradova IA et al. (2002, PMID 12660839) gave per-os Vilon and Epitalon to aged rats for one month and observed changes in small-intestine epithelial and subepithelial enzyme function. Both are rat studies — informative for proof-of-administration but not for human dosing.
No published study has measured oral Vilon plasma exposure, peripheral immune-cell readouts, or recovery outcomes in humans. Dipeptide oral bioavailability is biologically plausible (di- and tripeptides can survive intestinal hydrolysis better than larger peptides), but plausibility is not evidence. Community capsule products predate the human data.
X / Twitter discussions from @limitlesstack and @BasedBiohacker frame Vilon as part of a "bioregulator trinity" — Vilon (thymus, morning), Pinealon (brain, day), Epitalon (pineal, night). Reported regimens: 1–2 mg oral capsules taken empty-stomach in the morning, 30-day cycles. Self-reported effects: energy, faster workout recovery, fewer sick days. Treat as user testimony, not clinical evidence — n=few, no controls, no blinding, commercial affiliation on at least one source.
Oral Vilon is closer to "early signal" than "established protocol." The Khavinson rodent work suggests something gets absorbed and acts; the community stack is a hypothesis being tested in real time. If you are researching it, anchor your expectations to the published readouts (intestinal enzyme activity) rather than the social-media outcome claims (cognition, vitality, immunity).
Study Citations
Self-Assessment
Who Researches Vilon?
This Research Is Commonly Explored By People Who...
- Are interested in thymus-derived immune modulation and aging
- Want to understand the Khavinson bioregulator approach to immunosenescence
- Are exploring peptide-based immune support beyond traditional supplements
- Follow longevity research related to thymic involution
This Research May Not Be Relevant If...
- You want strong human clinical trial evidence — it doesn't exist for Vilon
- You expect dramatic immune boosting — bioregulators work subtly
- You want FDA-approved immune modulators
Want the Complete Protocol Guide?
Dosing schedules, interaction warnings, and cycle protocols for 50+ compounds — all in one place.
Get the Guide →
Key Takeaways
- Smallest Khavinson bioregulator — just 2 amino acids
- Derived from thymus tissue (Thymalin active component)
- Inhibited tumor growth in mice
- Modulates immune cell gene expression in vitro
- Oral administration affects intestinal enzyme activity in aged rats (PMID 11586413, 12660839)
- Published in PMC-indexed journals
- No human clinical trials
- Exact mechanism of DNA interaction at dipeptide level debated
- Not FDA approved
- Long-term effects unknown
- No human bioavailability data for the oral form — community capsule reports are anecdotal
🔬 Verified Research Source
Third-party tested compounds from Swiss Chems — one of the most trusted research suppliers.
Affiliate link — supports HighPeptides at no extra cost.
Research Supplies
Tools and supplies relevant to this research area.
As an Amazon Associate, HighPeptides earns from qualifying purchases.
Vilon is NOT FDA approved and is available only for research purposes. This page is for educational purposes only. Not medical advice. Research Only